About this Research Topic
Hyperglycemia has been recognized as a severe prognostic factor for patients affected by coronary artery obstruction. So far, a direct relationship between hyperglycemia, either as admission hyperglycemia or new diagnosis of diabetes, and inflammation has been documented. A rise in plasma interleukin-6 and TNF-a are the most validated biomarkers to support such a hypothesis. In vitro or in animal models, hyperglycemia deranges the cardiac cell elasticity and contractility while smooth muscle cells are prone to develop greater vascular rigidity. Hyperglycemia-mediated oxidative stress and sympathetic tone overactivity seem to be responsible for such negative findings. Whether antidiabetic therapy by itself or combined with other anti-inflammatory and anti-aggregating drugs may help prevent cardiovascular deaths in such patients is still debated.
In this Research Topic, we would like to address the possible role of the new anti-diabetic drugs either alone or in combination with anti-inflammatory medications and/or anti-aggregating drugs to treat the hyperglycemia-related deranging effect of cardiac activity and vascular reactivity. Indeed, it is well known that hyperglycemia might produce a significant derangement of vascular endothelium, which on the other hand is also associated with a decline in vascular and cardia performance and at cardiovascular death. So far, possible role of anti-diabetic drugs in the prevention of cardiovascular deaths should also be evaluated.
This Research Topic will highlight the new advancement in the therapeutic processes associated with a better gluco-metabolic control and reduced cardiovascular risk/s. For such reasons, the use of new antidiabetic agents such SGLT2 and long acting glucagon-like-peptide-1-receptor agonist as cardiovascular agents and potential anti-atherosclerotic drugs should be evaluated. We invite manuscripts detailing such drug actions in molecular investigations or in clinical trials. Possible physio-pathological findings derived by clinical investigations or along with devices of invasive and non-invasive procedures could be also useful to complete the data collected. Review articles are also welcomed in order to provide a deep overview of such complex metabolic-cardiovascular network.
In this Research Topic, we would like to address the possible role of the new anti-diabetic drugs either alone or in combination with anti-inflammatory medications and/or anti-aggregating drugs to treat the hyperglycemia-related deranging effect of cardiac activity and vascular reactivity. Indeed, it is well known that hyperglycemia might produce a significant derangement of vascular endothelium, which on the other hand is also associated with a decline in vascular and cardia performance and at cardiovascular death. So far, possible role of anti-diabetic drugs in the prevention of cardiovascular deaths should also be evaluated.
This Research Topic will highlight the new advancement in the therapeutic processes associated with a better gluco-metabolic control and reduced cardiovascular risk/s. For such reasons, the use of new antidiabetic agents such SGLT2 and long acting glucagon-like-peptide-1-receptor agonist as cardiovascular agents and potential anti-atherosclerotic drugs should be evaluated. We invite manuscripts detailing such drug actions in molecular investigations or in clinical trials. Possible physio-pathological findings derived by clinical investigations or along with devices of invasive and non-invasive procedures could be also useful to complete the data collected. Review articles are also welcomed in order to provide a deep overview of such complex metabolic-cardiovascular network.
Keywords: Hyperglycemia, coronary artery obstruction, diabetes, macro-angiopathy, MIOCA, MINOCA
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
